

ASX ANNOUNCEMENT

30 August 2022

Notice of date of AGM and other relevant dates

30 August 2022 – Pursuant to ASX Listing Rule 3.13.1, Cann Group Limited (ASX: CAN) (Cann or the Company) is pleased to advise the following details in relation to the Company's forthcoming Annual General Meeting (**AGM**):

<i>Date & time for AGM:</i>	Tuesday, 25 October 2022 at 10.00am (Melbourne time)
<i>Date of Notice of Meeting dispatch:</i>	Thursday, 22 September 2022
<i>Last date for receipt of nominations as a director:</i>	Tuesday, 6 September 2022

Further details in relation to the AGM, including items of business to be voted upon by shareholders, and instructions on how shareholders may attend and vote at the meeting, will be provided in the Notice of Meeting.

The Company's Appendix 4E, together with the FY22 Annual Report were released to the ASX on 29 August 2022 and can be accessed and downloaded from the Company's website [here](#).

Shareholders may obtain a hard copy of the Annual Report by emailing a request to the Company at communications@canngrouplimited.com.

The Company looks forward to shareholders participating at this year's AGM.

Authorised for release by Geraldine Farrell, Company Secretary, Cann Group Limited.

For all media enquiries please contact:

Rhys Cohen
Senior Corporate Communications Manager
+61 449 679 095
rhys.cohen@canngrouplimited.com

For all other information please contact:

Peter Crock
CEO
Cann Group Limited
+61 3 9095 7088
contact@canngrouplimited.com

Deborah Ambrosini
CFO
Cann Group Limited
+61 3 9095 7088
deborah.ambrosini@canngrouplimited.com

About Cann Group

Cann Group Limited (ABN 25 603 949 739) is enhancing patients' lives by developing, producing, and supplying innovative cannabis medicines. The Company has built world-class research, cultivation and GMP manufacturing facilities in Melbourne, and a state-of-the-art large-scale cultivation and GMP manufacturing facility near Mildura, Victoria. Cann Group supplies a range of dried flower and oil products, as well as active pharmaceutical ingredients and extracts, to customers in Australia and around the world. Cann Group also owns Satipharm and its patent-protected capsule technology.

Learn more at: www.canngrouplimited.com | www.satipharm.com